omeprazole

P1, N=24, Completed, Neurodawn Pharmaceutical Co., Ltd. | Recruiting --> Completed

P1, N=40, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

To improve the permeability across blood-brain tumor barrier (BTB), minoxidil sulfate (MS) and T7 peptide are modified on Cu-OME SNDs to produce Cu-OME/MS@T7 SNDs. Meanwhile, the released OME further blocks copper efflux by suppressing ATP7A copper efflux transporter. Collectively, this work demonstrates the effectiveness of OME-mediated copper delivery in inducing copper dyshomeostasis and triggering cuproptosis, highlighting a promising therapeutic approach through synchronous remodeling of copper influx and efflux.

P1, N=16, Completed, Providence Health & Services | Active, not recruiting --> Completed

P1, N=16, Recruiting, SpringWorks Therapeutics, Inc.

The effective treatment rate in patients of TG post-treatment (92.73%) was higher than CG (78.18%) (P<0.05). Matrine combined with omeprazole enteric-coated tablets significantly improved gastric mucosal histopathology, reduced inflammatory cytokine levels, enhanced gastric function, and increased the H. pylori eradication rate compared to omeprazole monotherapy.

P4, N=96, Recruiting, Odense University Hospital | Not yet recruiting --> Recruiting

P1, N=28, Recruiting, Institut de Recherches Internationales Servier (I.R.I.S.)

This study sheds light on the molecular mechanisms of KRAS-mutated CRC, emphasizing IL1B as a prognostic marker. Among the identified therapeutic agents, Omeprazole demonstrated the strongest interaction with AHR, suggesting a potential for repurposing in CRC treatment, while IL1B-targeting inhibitors such as Canakinumab emerged as selective candidates for modulating tumor-promoting inflammation. Novel genes such as EPSTI1, COL20A1, CDH1, and SOX9 warrant further investigation.

A clinical drug-drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered as a cocktail (Inje). Based on these results regarding co-administration with encorafenib, sensitive substrates of CYP3A should be avoided or dose adjusted based on the recommendations of their approved product labeling. This information has been included in the updated prescribing information for encorafenib.

P1, N=32, Not yet recruiting, Bristol-Myers Squibb

P1, N=18, Completed, The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University